Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

PAHC vs ZTS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PAHC
Phibro Animal Health Corporation

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$2.38B
5Y Perf.+123.8%
ZTS
Zoetis Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • US
Market Cap$46.95B
5Y Perf.-20.2%

PAHC vs ZTS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PAHC logoPAHC
ZTS logoZTS
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & Generic
Market Cap$2.38B$46.95B
Revenue (TTM)$1.46B$9.47B
Net Income (TTM)$92M$2.67B
Gross Margin31.9%70.5%
Operating Margin11.6%38.0%
Forward P/E19.3x15.8x
Total Debt$762M$9.49B
Cash & Equiv.$68M$2.31B

PAHC vs ZTSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PAHC
ZTS
StockMay 20May 26Return
Phibro Animal Healt… (PAHC)100223.8+123.8%
Zoetis Inc. (ZTS)10079.8-20.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: PAHC vs ZTS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ZTS leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Phibro Animal Health Corporation is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
PAHC
Phibro Animal Health Corporation
The Growth Play

PAHC is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 27.4%, EPS growth 18.8%, 3Y rev CAGR 11.2%
  • 207.3% 10Y total return vs ZTS's 158.5%
  • 27.4% revenue growth vs ZTS's 2.3%
Best for: growth exposure and long-term compounding
ZTS
Zoetis Inc.
The Income Pick

ZTS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • Dividend streak 13 yrs, beta 0.90, yield 1.8%
  • Lower volatility, beta 0.90, current ratio 3.03x
  • PEG 1.32 vs PAHC's 2.59
Best for: income & stability and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthPAHC logoPAHC27.4% revenue growth vs ZTS's 2.3%
ValueZTS logoZTSLower P/E (15.8x vs 19.3x), PEG 1.32 vs 2.59
Quality / MarginsZTS logoZTS28.2% margin vs PAHC's 6.3%
Stability / SafetyZTS logoZTSBeta 0.90 vs PAHC's 1.38
DividendsZTS logoZTS1.8% yield, 13-year raise streak, vs PAHC's 0.8%
Momentum (1Y)PAHC logoPAHC+210.5% vs ZTS's -24.4%
Efficiency (ROA)ZTS logoZTS18.1% ROA vs PAHC's 6.7%, ROIC 26.9% vs 9.8%

PAHC vs ZTS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

PAHCPhibro Animal Health Corporation
FY 2025
Vaccines
100.0%$137M
ZTSZoetis Inc.
FY 2025
Horses
67.8%$6.3B
Cattle
16.1%$1.5B
Swine
5.0%$466M
Poultry
4.7%$432M
Dogs and Cats
3.3%$304M
Fish
3.1%$286M

PAHC vs ZTS — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLZTSLAGGINGPAHC

Income & Cash Flow (Last 12 Months)

ZTS leads this category, winning 4 of 6 comparable metrics.

ZTS is the larger business by revenue, generating $9.5B annually — 6.5x PAHC's $1.5B. ZTS is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to PAHC's 6.3%. On growth, PAHC holds the edge at +20.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricPAHC logoPAHCPhibro Animal Hea…ZTS logoZTSZoetis Inc.
RevenueTrailing 12 months$1.5B$9.5B
EBITDAEarnings before interest/tax$220M$4.1B
Net IncomeAfter-tax profit$92M$2.7B
Free Cash FlowCash after capex$47M$2.3B
Gross MarginGross profit ÷ Revenue+31.9%+70.5%
Operating MarginEBIT ÷ Revenue+11.6%+38.0%
Net MarginNet income ÷ Revenue+6.3%+28.2%
FCF MarginFCF ÷ Revenue+3.2%+24.1%
Rev. Growth (YoY)Latest quarter vs prior year+20.9%+3.0%
EPS Growth (YoY)Latest quarter vs prior year+7.4%+6.2%
ZTS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

ZTS leads this category, winning 5 of 7 comparable metrics.

At 18.5x trailing earnings, ZTS trades at a 63% valuation discount to PAHC's 49.3x P/E. Adjusting for growth (PEG ratio), ZTS offers better value at 1.54x vs PAHC's 6.60x — a lower PEG means you pay less per unit of expected earnings growth.

MetricPAHC logoPAHCPhibro Animal Hea…ZTS logoZTSZoetis Inc.
Market CapShares × price$2.4B$46.9B
Enterprise ValueMkt cap + debt − cash$3.1B$54.1B
Trailing P/EPrice ÷ TTM EPS49.28x18.48x
Forward P/EPrice ÷ next-FY EPS est.19.33x15.83x
PEG RatioP/E ÷ EPS growth rate6.60x1.54x
EV / EBITDAEnterprise value multiple19.67x13.25x
Price / SalesMarket cap ÷ Revenue1.83x4.96x
Price / BookPrice ÷ Book value/share8.35x14.82x
Price / FCFMarket cap ÷ FCF56.82x20.56x
ZTS leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

ZTS leads this category, winning 6 of 9 comparable metrics.

ZTS delivers a 58.2% return on equity — every $100 of shareholder capital generates $58 in annual profit, vs $31 for PAHC. PAHC carries lower financial leverage with a 2.67x debt-to-equity ratio, signaling a more conservative balance sheet compared to ZTS's 2.85x. On the Piotroski fundamental quality scale (0–9), ZTS scores 7/9 vs PAHC's 5/9, reflecting strong financial health.

MetricPAHC logoPAHCPhibro Animal Hea…ZTS logoZTSZoetis Inc.
ROE (TTM)Return on equity+30.8%+58.2%
ROA (TTM)Return on assets+6.7%+18.1%
ROICReturn on invested capital+9.8%+26.9%
ROCEReturn on capital employed+12.0%+29.9%
Piotroski ScoreFundamental quality 0–957
Debt / EquityFinancial leverage2.67x2.85x
Net DebtTotal debt minus cash$694M$7.2B
Cash & Equiv.Liquid assets$68M$2.3B
Total DebtShort + long-term debt$762M$9.5B
Interest CoverageEBIT ÷ Interest expense3.64x15.13x
ZTS leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

PAHC leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in PAHC five years ago would be worth $23,641 today (with dividends reinvested), compared to $7,122 for ZTS. Over the past 12 months, PAHC leads with a +210.5% total return vs ZTS's -24.4%. The 3-year compound annual growth rate (CAGR) favors PAHC at 61.1% vs ZTS's -14.2% — a key indicator of consistent wealth creation.

MetricPAHC logoPAHCPhibro Animal Hea…ZTS logoZTSZoetis Inc.
YTD ReturnYear-to-date+57.5%-10.8%
1-Year ReturnPast 12 months+210.5%-24.4%
3-Year ReturnCumulative with dividends+318.1%-36.8%
5-Year ReturnCumulative with dividends+136.4%-28.8%
10-Year ReturnCumulative with dividends+207.3%+158.5%
CAGR (3Y)Annualised 3-year return+61.1%-14.2%
PAHC leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — PAHC and ZTS each lead in 1 of 2 comparable metrics.

ZTS is the less volatile stock with a 0.90 beta — it tends to amplify market swings less than PAHC's 1.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PAHC currently trades 97.6% from its 52-week high vs ZTS's 64.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPAHC logoPAHCPhibro Animal Hea…ZTS logoZTSZoetis Inc.
Beta (5Y)Sensitivity to S&P 5001.38x0.90x
52-Week HighHighest price in past year$60.08$172.23
52-Week LowLowest price in past year$18.89$110.94
% of 52W HighCurrent price vs 52-week peak+97.6%+64.6%
RSI (14)Momentum oscillator 0–10054.537.4
Avg Volume (50D)Average daily shares traded273K3.2M
Evenly matched — PAHC and ZTS each lead in 1 of 2 comparable metrics.

Analyst Outlook

ZTS leads this category, winning 2 of 2 comparable metrics.

Wall Street rates PAHC as "Buy" and ZTS as "Hold". Consensus price targets imply 28.6% upside for ZTS (target: $143) vs -16.4% for PAHC (target: $49). For income investors, ZTS offers the higher dividend yield at 1.80% vs PAHC's 0.81%.

MetricPAHC logoPAHCPhibro Animal Hea…ZTS logoZTSZoetis Inc.
Analyst RatingConsensus buy/hold/sellBuyHold
Price TargetConsensus 12-month target$49.00$143.00
# AnalystsCovering analysts1330
Dividend YieldAnnual dividend ÷ price+0.8%+1.8%
Dividend StreakConsecutive years of raises013
Dividend / ShareAnnual DPS$0.48$2.00
Buyback YieldShare repurchases ÷ mkt cap0.0%+6.9%
ZTS leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

ZTS leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). PAHC leads in 1 (Total Returns). 1 tied.

Best OverallZoetis Inc. (ZTS)Leads 4 of 6 categories
Loading custom metrics...

PAHC vs ZTS: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is PAHC or ZTS a better buy right now?

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus 2. 3% for Zoetis Inc. (ZTS). Zoetis Inc. (ZTS) offers the better valuation at 18. 5x trailing P/E (15. 8x forward), making it the more compelling value choice. Analysts rate Phibro Animal Health Corporation (PAHC) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — PAHC or ZTS?

On trailing P/E, Zoetis Inc.

(ZTS) is the cheapest at 18. 5x versus Phibro Animal Health Corporation at 49. 3x. On forward P/E, Zoetis Inc. is actually cheaper at 15. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Zoetis Inc. wins at 1. 32x versus Phibro Animal Health Corporation's 2. 59x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — PAHC or ZTS?

Over the past 5 years, Phibro Animal Health Corporation (PAHC) delivered a total return of +136.

4%, compared to -28. 8% for Zoetis Inc. (ZTS). Over 10 years, the gap is even starker: PAHC returned +207. 3% versus ZTS's +158. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — PAHC or ZTS?

By beta (market sensitivity over 5 years), Zoetis Inc.

(ZTS) is the lower-risk stock at 0. 90β versus Phibro Animal Health Corporation's 1. 38β — meaning PAHC is approximately 52% more volatile than ZTS relative to the S&P 500. On balance sheet safety, Phibro Animal Health Corporation (PAHC) carries a lower debt/equity ratio of 3% versus 3% for Zoetis Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — PAHC or ZTS?

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus 2. 3% for Zoetis Inc. (ZTS). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to 10. 1% for Zoetis Inc.. Over a 3-year CAGR, PAHC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — PAHC or ZTS?

Zoetis Inc.

(ZTS) is the more profitable company, earning 28. 2% net margin versus 3. 7% for Phibro Animal Health Corporation — meaning it keeps 28. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZTS leads at 38. 0% versus 8. 5% for PAHC. At the gross margin level — before operating expenses — ZTS leads at 70. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is PAHC or ZTS more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Zoetis Inc. (ZTS) is the more undervalued stock at a PEG of 1. 32x versus Phibro Animal Health Corporation's 2. 59x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Zoetis Inc. (ZTS) trades at 15. 8x forward P/E versus 19. 3x for Phibro Animal Health Corporation — 3. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZTS: 28. 6% to $143. 00.

08

Which pays a better dividend — PAHC or ZTS?

All stocks in this comparison pay dividends.

Zoetis Inc. (ZTS) offers the highest yield at 1. 8%, versus 0. 8% for Phibro Animal Health Corporation (PAHC).

09

Is PAHC or ZTS better for a retirement portfolio?

For long-horizon retirement investors, Zoetis Inc.

(ZTS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), 1. 8% yield, +158. 5% 10Y return). Both have compounded well over 10 years (ZTS: +158. 5%, PAHC: +207. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between PAHC and ZTS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PAHC is a small-cap high-growth stock; ZTS is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

PAHC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Net Margin > 5%
Run This Screen
Stocks Like

ZTS

Dividend Mega-Cap Quality

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 16%
  • Dividend Yield > 0.7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform PAHC and ZTS on the metrics below

Revenue Growth>
%
(PAHC: 20.9% · ZTS: 3.0%)
Net Margin>
%
(PAHC: 6.3% · ZTS: 28.2%)
P/E Ratio<
x
(PAHC: 49.3x · ZTS: 18.5x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.